| Trial ID: | L7386 |
| Source ID: | NCT00555451
|
| Associated Drug: |
He3286
|
| Title: |
Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Insulin Resistance
|
| Interventions: |
DRUG: HE3286
|
| Outcome Measures: |
Primary: safety and pharmacokinetics, Duration of the study | Secondary: To assess the potential activity of HE3286 to decrease insulin resistance, duration of study
|
| Sponsor/Collaborators: |
Sponsor: Harbor Therapeutics
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-10
|
| Completion Date: |
2009-09
|
| Results First Posted: |
|
| Last Update Posted: |
2010-05-13
|
| Locations: |
Baton Rouge, Louisiana, 70808, United States|dgd Research, Inc., San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00555451
|
